1362819-19-9

Upstream product

• 39503-57-6 methyl 5-bromo-2-hydroxy-4-methylbenzoate 
• 108-24-7 acetic anhydride 
• 50-85-1 2-hydroxy-p-toluic acid 

Downstream Products

• 1362820-36-7 phenylmethyl 4-[(dimethylamino)carbonyl]-5-(1-methyl-1H-pyrazol-4-yl)-2-[(phenylmethyl)oxy]benzoate 
• 1362820-30-1 phenylmethyl 5-bromo-4-[(dimethylamino)carbonyl]-2-[(phenylmethyl)oxy]benzoate 
• 1362820-27-6 5-(1-methyl-1H-pyrazol-4-yl)-2-[(phenylmethyl)oxy]-4-(1-piperidinylcarbonyl)benzoic acid 
• 1362820-25-4 phenylmethyl 5-(1-methyl-1H-pyrazol-4-yl)-2-[(phenylmethyl)oxy]-4-(1-piperidinylcarbonyl)benzoate 
• 1362820-22-1 phenylmethyl 5-bromo-2-[(phenylmethyl)oxy]-4-(1-piperidinylcarbonyl)benzoate 
• 1362820-33-4 2-bromo-5-[(phenylmethyl)oxy]-4-{[(phenylmethyl)oxy]carbonyl}benzoic acid 
• 1362819-98-4 (4-fluorophenyl)methyl 5-bromo-2-{[(4-fluorophenyl)methyl]oxy}-4-(4-morpholinylcarbonyl)benzoate 
• 1362819-95-1 (4-fluorophenyl)methyl 5-bromo-2-{[(4-fluorophenyl)methyl]oxy}-4-formylbenzoate 
• 1362819-91-7 5-(1-methyl-1H-pyrazol-4-yl)-4-(4-morpholinylcarbonyl)-2-[(phenylmethyl)oxy]benzoic acid 
• 1362819-88-2 phenylmethyl 5-bromo-4-(4-morpholinylcarbonyl)-2-[(phenylmethyl)oxy]benzoate 
• 1362819-85-9 phenylmethyl 5-bromo-4-formyl-2-[(phenylmethyl)oxy]benzoate 
• 1362819-79-1 5-bromo-2-{[(2,4-difluorophenyl)methyl]oxy}-4-(4-morpholinylmethyl)benzoic acid 
• 1362819-76-8 (2,4-difluorophenyl)methyl 5-bromo-2-{[(2,4-difluorophenyl)methyl]oxy}-4-(4-morpholinylmethyl)benzoate 
• 1362819-73-5 5-bromo-2-{[(4-fluorophenyl)methyl]oxy}-4-(4-morpholinylmethyl)benzoic acid 

Relevant academic research and scientific papers

NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE

A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compoun

2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by LRRK2 kinase activity, for example Parkinson's disease or Alzheimer's disease.